Ryvu Therapeutics SA

NEW
WAR:RVU (Poland)  
zł 41.50 (-15.05%) Dec 12
At Loss
P/B:
6.51
Market Cap:
zł 1.13B ($ 234.54M)
Enterprise V:
zł 956.54M ($ 192.32M)
Volume:
52.85K
Avg Vol (2M):
7.57K
Warning! GuruFocus detected 4 Severe warning signs with RVU. Try a 7-Day Free Trial to check it out.
Trade In:
Volume:
52.85K
Market Cap zł:
1.13B
Market Cap $:
234.54M
At Loss
Avg Vol (2M):
7.57K
Enterprise Value zł:
956.54M
Enterprise Value $:
192.32M
PB Ratio:
6.51
Website Sources Stock PDF
Dataset
Financial Download GuruFocus Premium Icon Manual of Stocksâ„¢

Business Description

Ryvu Therapeutics SA
NAICS : 325412 SIC : 2834
ISIN : PLSELVT00013
https://www.ryvu.com
Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Compare
Compare
WAR:CTXWAR:SVEWAR:BIOWAR:MABWAR:PTGWAR:BCXWAR:MOCWAR:URTWAR:PHRWAR:PUROCSE:NOVO BVRTXREGNASX:CSLSGENXKRX:207940MRNAHKSE:02269XBRU:ARGXBNTX
Traded in other countries / regions
RVU.Poland9Y4.Germany
IPO Date
2011-07-14
Description
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.

Financial Strength

4/10
Name Current Vs Industry Vs History
Cash-To-Debt 3.39
Equity-to-Asset 0.44
Debt-to-Equity 0.41
Debt-to-EBITDA -0.79
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.73
Distress
Grey
Safe
Beneish M-Score -3.06
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

9/10
Name Current Vs Industry Vs History
3-Year Revenue Growth Rate 30.6
3-Year EBITDA Growth Rate -49.2
3-Year EPS without NRI Growth Rate -28.4
3-Year FCF Growth Rate -15
3-Year Book Growth Rate -1.7
Future 3-5Y Total Revenue Growth Rate Estimate 74.41

Momentum Rank

7/10
Name Current Vs Industry Vs History
5-Day RSI 15.85
9-Day RSI 28.9
14-Day RSI 35.49
3-1 Month Momentum % -19.52
6-1 Month Momentum % -18.47
12-1 Month Momentum % -32.46

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.03
Quick Ratio 3.01
Cash Ratio 2.51
Days Inventory 45.56
Days Sales Outstanding 75.47
Days Payable 514.09

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -8
Shareholder Yield % -3.1

Profitability Rank

3/10
Name Current Vs Industry Vs History
Gross Margin % 70.63
Operating Margin % -164.93
Net Margin % -163.69
FCF Margin % -206.98
ROE % -46.31
ROA % -25.3
ROIC % -63.43
3-Year ROIIC % -252.52
ROC (Joel Greenblatt) % -133.98
ROCE % -30.45
Years of Profitability over Past 10-Year 5

GF Value Rank

4/10
Name Current Vs Industry Vs History
Forward PE Ratio 93.46
Shiller PE Ratio 6.4
PS Ratio 18.1
PB Ratio 6.51
Price-to-Tangible-Book 5.65
EV-to-EBIT -7.73
EV-to-EBITDA -8.63
EV-to-Revenue 12.37
EV-to-FCF -7.48
Price-to-GF-Value 0.37
Price-to-Median-PS-Value 0.79
Price-to-Net-Current-Asset-Value 13.65
Price-to-Net-Cash 48.82
Earnings Yield (Greenblatt) % -12.93
FCF Yield % -13.67

Financials (Next Earnings Date:2025-03-22 Est.)

WAR:RVU's 30-Y Financials
AAPL
Income Statement Breakdown FY
No Enough Data
AAPL
Balance Sheet Breakdown
No Enough Data
AAPL
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Ryvu Therapeutics SA Executives

Details

GF Value: zł112.77

WAR:RVU

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil zł) 63.618
EPS (TTM) (zł) -4.5
Beta 2.24
3-Year Sharpe Ratio -0.12
3-Year Sortino Ratio -0.19
Volatility % 25.93
14-Day RSI 35.49
14-Day ATR (zł) 2.741135
20-Day SMA (zł) 46.5175
12-1 Month Momentum % -32.46
52-Week Range (zł) 39.5 - 65
Shares Outstanding (Mil) 23.12

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Ryvu Therapeutics SA Filings

Filing Date Document Date Form
No Filing Data

Ryvu Therapeutics SA Stock Events

Financials Calendars
Event Date Price (zł)
No Event Data

Ryvu Therapeutics SA Frequently Asked Questions

What is Ryvu Therapeutics SA(WAR:RVU)'s stock price today?
The current price of WAR:RVU is zł41.50. The 52 week high of WAR:RVU is zł65.00 and 52 week low is zł39.50.
When is next earnings date of Ryvu Therapeutics SA(WAR:RVU)?
The next earnings date of Ryvu Therapeutics SA(WAR:RVU) is 2025-03-22 Est..
Does Ryvu Therapeutics SA(WAR:RVU) pay dividends? If so, how much?
Ryvu Therapeutics SA(WAR:RVU) does not pay dividend.

Press Release

Subject Date
No Press Release
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.